Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6188)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2014 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol 2014; 20(21): 6691-6697 [PMID: 24914397 DOI: 10.3748/wjg.v20.i21.6691] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i21/6691.htm |
| Number | Citing Articles |
| 1 |
Mei Guan, Yan-Ping Zhou, Jin-Lu Sun, Shu-Chang Chen. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/428169
|
| 2 |
Sergio Racchiusa, Enricomaria Mormina, Antonietta Ax, Olimpia Musumeci, Marcello Longo, Francesca Granata. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature. Neurological Sciences 2019; 40(5): 915 doi: 10.1007/s10072-018-3651-4
|
| 3 |
Jae Hyun Kim, Seun Ja Park. Target Therapy in Unresectable or Metastatic Colorectal Cancer. The Korean Journal of Gastroenterology 2016; 68(6): 303 doi: 10.4166/kjg.2016.68.6.303
|
| 4 |
Jennifer Massey. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU. Journal of Clinical Neuroscience 2017; 40: 57 doi: 10.1016/j.jocn.2017.01.005
|
| 5 |
Rashmi R. Shah. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?. Drug Safety 2017; 40(5): 373 doi: 10.1007/s40264-017-0508-3
|
| 6 |
Stephanie A. Holler Howard, Katherine M. Krajewski, Jyothi P. Jagannathan, Marta Braschi-Amirfarzan, Sree H. Tirumani, Atul B. Shinagare, Nikhil H. Ramaiya. A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. American Journal of Roentgenology 2016; 207(1): 4 doi: 10.2214/AJR.15.15480
|
| 7 |
Fangfang Shi, Liwei Shen, Yonghui Shi, Lei Shi, Xiaoli Yang, Zhi Jin, Wenpeng Liu, Danhong Wu. Posterior reversible encephalopathy syndrome after postpartum hemorrhage and uterine artery embolization. Medicine 2017; 96(49): e8973 doi: 10.1097/MD.0000000000008973
|
| 8 |
Andrew King, Mirjana Dimovska, Luke Bisoski. Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension. Current Hypertension Reports 2018; 20(1) doi: 10.1007/s11906-018-0807-9
|
| 9 |
Xiaomeng Zou, Peng Zhou, Wei Lv, Chuanyong Liu, Jie Liu. Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1126235
|
| 10 |
Melek Karakurt Eryılmaz, Hasan Mutlu, Derya Kıvrak Salim, Fatma Yalçın Musri, Hasan Şenol Coşkun. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. Journal of Oncology Pharmacy Practice 2016; 22(6): 806 doi: 10.1177/1078155215611048
|
| 11 |
|
| 12 |
J. Anakha, Prakashkumar Dobariya, Shyam Sunder Sharma, Abhay H. Pande. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status. Medical Oncology 2023; 41(1) doi: 10.1007/s12032-023-02245-w
|